Warfarin: An environment-dependent switchable molecular probe

Journal of Molecular Recognition

Volumn 23, Issue 6, 2010, Pages 604-608

  Nicholls, Ian A ^a,b   Karlsson, Björn C G ^a   Rosengren, Annika M ^a   Henschel, Henning ^a  

^a LINNAEUS UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Colloidal silica; Fluorescence; Fluorescence lifetimes; HSA; Human serum albumin; Molecular probe; Molecular recognition; Molecularly imprinted polymer; Organic solvents; TCSPC; Warfarin

Indexed keywords

4 HYDROXYCOUMARIN; 4 HYDROXYCOUMARIN DERIVATIVE; 4-HYDROXYCOUMARIN; WARFARIN;

ARTICLE; BIOLOGICAL MODEL; CHEMISTRY; ENVIRONMENT; FLUOROIMMUNOASSAY; GENETIC PROCEDURES; METABOLISM; METHODOLOGY; MOLECULAR PROBE; PROTEIN CONFORMATION; STRUCTURE ACTIVITY RELATION;

4-HYDROXYCOUMARINS; BIOSENSING TECHNIQUES; ENVIRONMENT; FLUOROIMMUNOASSAY; MODELS, BIOLOGICAL; MOLECULAR PROBE TECHNIQUES; MOLECULAR PROBES; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP; WARFARIN;

EID: 77956717111     PISSN: 09523499     EISSN: 10991352     Source Type: Journal    
DOI: 10.1002/jmr.1058     Document Type: Article

References (35)

1. Alexander CJ, Andersson HS, Andersson LI, Ansell RJ, Kirsch N, Nicholls IA, O'Mahony J, Whitcombe MJ. 2006. Molecular imprinting science and technology: a survey of the literature for the years up to and including 2003. J. Mol. Recognit. 19: 106-180.
2. Ammar H, Fery-Forgues S, El Gharbi R. 2003. UV/vis absorption and fluorescence spectroscopic study of novel symmetrical biscoumarin dyes. Dyes Pigments 57: 259-265.
3. de Melo J, Fernandes P. 2001. Spectroscopy and photophysics of 4-and 7-hydroxycoumarins and their thione analogs. J. Mol. Struct. 565: 69-78.
4. de Melo J, Becker R, Macanita A. 1994. Photophysical behaviour of coumarins as a function of substitution and solvent - experimental-evidence for the existance of a lowest lying (1)επ× state. J. Phys. Chem. 98: 6054-6058.
5. Gao F, Li H, Yang Y. 2000. Influence of the molecular structure and medium on the absorption and emission character of ketocoumarin derivatives and probability of as fluorescence probes. Dyes Pigments 47: 231-238.
6. Gebauer M. 2007. Synthesis and structure-activity relationships of novel warfarin derivatives. Bioorg. Med. Chem. 15: 2414-2420.
7. Ha CE, Petersen CE, Park DS, Harohalli K, Bhagavan NV. 2000. Investigations on the effects of ethanol on warfarin binding to human serum albumin. J. Biomed. Sci. 7: 114-121.
8. He MX, Korzekwa KR, Jones JP, Rettie AE, Trager WF. 1999. Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9. Arch. Biochem. Biophys. 372: 16-28.
9. Heimark LD, Trager WF. 1984. The preferred solution conformation of warfarin at the active site of cytochrome P-450 based on the CD spectra in octanol/water model system. J. Med. Chem. 27: 1092-1095.
10. Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, Wells PS. 2005. Systematic overview of warfarin and its drug and food interactions. Arch. Intern. Med. 165: 1095-1106.
11. Il'ichev YV, Perry JL, Simon JD. 2002. Interaction of ochratoxin A with human serum albumin. A common binding site of ochratoxin A and warfarin in subdomain IIA. J. Phys. Chem. B 106: 460-465.
12. Ionescu S, Hillebrand M. 2003. Theoretical study of the excited states of 3-phenyl- and 3-thiophenyl-coumarins. Chem. Phys. 293: 53-64.
13. Ishiwata S, Kamiya M. 1997. Cyclodextrin inclusion effects on fluorescence and fluorimetric properties of the pesticide warfarin. Chemosphere 34: 783-789.
14. Karlsson JG, Andersson LI, Nicholls IA. 2001. Probing the molecular basis for ligand-selective recognition in molecularly imprinted polymers selective for the local anaesthetic bupivacaine. Anal. Chim. Acta 435: 57-64.
15. Karlsson JG, Karlsson B, Andersson LI, Nicholls IA. 2004. The roles of template complexation and ligand binding conditions on recognition in bupivacaine molecularly imprinted polymers. Analyst 129: 456-462.
16. Karlsson BCG, Rosengren AM, Andersson PO, Nicholls IA. 2007. The spectrophysics of warfarin: implications for protein binding. J. Phys. Chem. B 111: 10520-10528.
17. Karlsson BCG, Rosengren AM, Andersson PO, Nicholls IA. 2009. Molecular insights on the two fluorescence lifetimes displayed by warfarin from fluorescence anisotropy and molecular dynamics studies. J. Phys. Chem. B 113: 7945-7949.
18. Lakowicz JR. 1999. Principles of Fluorescence Spectroscopy. 2nd edn. Kluwer Academic/Plenum publishers: New York.
19. Landefeld C, Beyth R. 1993. Anticoagulant-related bleeding - epidemiology, prediction and prevention. Am. J. Med. 95: 315-328.
20. Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, Stafford DW. 2004. Identification of the gene for vitamin K epoxide reductase. Nature 427: 541-544.
21. Machado AED, de Miranda JA, de Oliveira-Campos AMF, Severino D, Nicodem DE. 2001. Photophysical properties of two new psoralen analogs. J. Photochem. Photobiol. 146: 75-81.
22. Machado AED, de Miranda JA, Guilardi S, Nicodem DE, Severino D. 2003. Photophysics and spectroscopic properties of 3-benzoxazol-2-yl-chromen-2-one. Spectrochim. Acta Part A 59: 345-355.
23. Mantulin WW, Song P. 1973. Excited states of skin-sensitizing coumarins and psoralens. Spectroscopic studies. J. Am. Chem. Soc. 95: 5122-5129.
24. Petersen CE, Ha CE, Curry S, Bhagavan NV. 2002. Probing the structure of the warfarin-binding-site on human serum albumin using site-directed mutagenesis. Proteins: Struct. Funct. Gen. 47: 116-125.
25. Petitpas I, Bhattacharya AA, Twine S, East M, Curry S. 2001. Crystal structure analysis of warfarin binding to human serum albumin. Anatomy of drug site I. J. Biol. Chem. 276: 22804-22809.
26. Reichardt C. 1994. Solvatochromic dyes as solvent polarity indicators. Chem. Rev. 94: 2319-2358.
27. Rosengren AM, Karlsson JG, Andersson PO, Nicholls IA. 2005. Chemometric models of molecularly imprinted polymer - template binding. Anal. Chem. 77: 5700-5705.
28. Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hortnagel K, Pelz HJ, Lappegard K, Seifried E, Scharrer I, Tuddenham EGD, Muller CR, Strom TM, Oldenburg J. 2004. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427: 537-541.
29. Sharma VK, Saharo PD, Sharma N, Rastogi RC, Ghoshal SK, Mohan D. 2003. Influence of solvent and substituent on excited state characterstics of laser grade coumarin dyes. Spectrochim. Acta Part A 59: 1161-1170.
30. Song P, Gordon WH. 1970. Spectroscopic study of the excited states of coumarin. J. Phys. Chem. 74: 4234-4240.
31. Valente EJ, Trager WF, Jensen LH. 1975. The crystal and molecular structure and absolute configuration of (-)-(S)-warfarin. Acta Crystallogr. B 31: 954-960.
32. Valente EJ, Lingafelter WF, Porter WR, Trager WF. 1977. Structure of warfarin in solution. J. Med. Chem. 20: 1489-1493.
33. Valente EJ, Porter WR, Trager WF. 1978. Conformations of selected 3-substituted 4-hydroxycoumarins in solution by nuclear magnetic resonance. Warfarin and phenprocoumon. J. Med. Chem. 21: 231-234.
34. Vasquez JM, Vu A, Schultz JS, Vullev VI. 2009. Fluorescence enhancement of warfarin induced by interaction with beta-cyclodextrin. Biotechnol. Prog. 25: 906-914.
35. Yacobi A, Udall JA, Levy G. 1976. Serum-protein binding as a determinant of warfarin body clearance and anticoagulant effect in patients with cardiovascular-disease. Clin. Pharmacol. Ther. 19: 120.